STOCKHOLM, July 8 (Reuters) - Swedish medical technology
group Vitrolife VITR.ST said on Thursday it would buy
reproductive genetic testing services provider Igenomix S.L. in
a deal worth 1.25 billion euros ($1.48 billion) on a cash and
debt free basis.
The deal with private equity group EQT EQTAB.ST and other
shareholders would be financed through a mix of shares issued to
the sellers, a directed share issue to institutional investors,
new debt and its own cash, Vitrolife said.
"The combination will create a global leader in reproductive
health by combining the knowledge, product portfolios and market
presence of two leading companies within IVF medical devices and
reproductive genetic testing services," it said in statement.
Igenomix provides reproductive genetic testing services for
In vitro fertilization (IVF) clinics and operates
26 labs globally, Vitrolife said.
($1 = 0.8447 euros)
(Reporting by Niklas Pollard; editing by Johan Ahlander)
((Niklas.Pollard@thomsonreuters.com;))